176 related articles for article (PubMed ID: 37833878)
21. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat.
Abalo R; Cabezos PA; López-Miranda V; Vera G; González C; Castillo M; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2009 Sep; 21(9):1002-e80. PubMed ID: 19413685
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain.
Sekiguchi F; Kawara Y; Tsubota M; Kawakami E; Ozaki T; Kawaishi Y; Tomita S; Kanaoka D; Yoshida S; Ohkubo T; Kawabata A
Pain; 2016 Aug; 157(8):1655-1665. PubMed ID: 27023424
[TBL] [Abstract][Full Text] [Related]
23. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
24. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis.
Zhang L; Kline RH; McNearney TA; Johnson MP; Westlund KN
Mol Pain; 2014 Nov; 10():66. PubMed ID: 25403433
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
27. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.
Yu XH; Cao CQ; Martino G; Puma C; Morinville A; St-Onge S; Lessard É; Perkins MN; Laird JMA
Pain; 2010 Nov; 151(2):337-344. PubMed ID: 20696525
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells.
Xian XS; Park H; Choi MG; Park JM
Anticancer Res; 2013 Jun; 33(6):2541-7. PubMed ID: 23749906
[TBL] [Abstract][Full Text] [Related]
29. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats.
Li J; Daughters RS; Bullis C; Bengiamin R; Stucky MW; Brennan J; Simone DA
Pain; 1999 May; 81(1-2):25-33. PubMed ID: 10353490
[TBL] [Abstract][Full Text] [Related]
30. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
31. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain.
Leichsenring A; Andriske M; Bäcker I; Stichel CC; Lübbert H
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jun; 379(6):627-36. PubMed ID: 19152053
[TBL] [Abstract][Full Text] [Related]
32. The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.
Uhelski ML; Cain DM; Harding-Rose C; Simone DA
Neuroscience; 2013 Sep; 247():84-94. PubMed ID: 23673278
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice.
Gunduz O; Topuz RD; Karadag CH; Ulugol A
Eur J Pain; 2016 Mar; 20(3):465-71. PubMed ID: 26206340
[TBL] [Abstract][Full Text] [Related]
34. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.
Lim G; Sung B; Ji RR; Mao J
Pain; 2003 Sep; 105(1-2):275-83. PubMed ID: 14499445
[TBL] [Abstract][Full Text] [Related]
36. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
37. Role of the cannabinoid signaling in the brain orexin- and ghrelin-induced visceral antinociception in conscious rats.
Okumura T; Nozu T; Kumei S; Ohhira M
J Pharmacol Sci; 2018 Jun; 137(2):230-232. PubMed ID: 29958814
[TBL] [Abstract][Full Text] [Related]
38. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
39. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
Adamson Barnes NS; Mitchell VA; Kazantzis NP; Vaughan CW
Br J Pharmacol; 2016 Jan; 173(1):77-87. PubMed ID: 26398331
[TBL] [Abstract][Full Text] [Related]
40. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
